Peter Drueckes

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 484 citations · Full text

Pharmaceutical Chemistry, Tumor Biology, Medicinal Chemistry +19

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini et al. · Journal of Medicinal Chemistry · 2018 · 432 citations · Full text

Drug Target, Mixed-phenotype Acute Leukemia, Molecular Biology +16

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Paul W. Manley, Peter Drueckes, Gabriele Fendrich et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2009 · 218 citations

Drug Target, Medicine, Receptor Tyrosine Kinase +8

A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients

Ralph Tiedt, Elisa Degenkolbe, Pascal Furet et al. · Cancer Research · 2011 · 133 citations · Full text

Mixed-phenotype Acute Leukemia, Cancer Patients, Tumor Biology +21

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

Fabienne Baffert, Catherine H. Régnier, Alain De Pover et al. · Molecular Cancer Therapeutics · 2010 · 119 citations

Pharmacotherapy, Excellent Selectivity, Pharmaceutical Chemistry +20